FAQ on Lp(a) Screening in Community Health Centers to Reduce Cardiovascular Disease Risk

What is lipoprotein(a) or Lp(a)?

Lipoprotein(a), or Lp(a), is an independent, inherited, and causal risk factor for cardiovascular disease, similar to LDL cholesterol but not affected by lifestyle changes.

Why is screening for Lp(a) important?

Screening for Lp(a) is crucial because it can provide lifelong insight into heart disease risk, especially for those with a family history or increased risk, yet many are unaware of their Lp(a) levels.

How does the Lp(a) Community Health Centers Discovery Project work?

The project increases awareness and improves shared decision-making between healthcare professionals and individuals in community health centers about Lp(a) screening and ASCVD risk management, with participating centers adding new screening processes.

Who is involved in the Lp(a) Community Health Centers Discovery Project?

The American Heart Association, supported by Novartis Pharmaceuticals Corporation, and community health centers across the U.S. are involved, with 10 centers participating initially and 10 more to be added.

Where is the Lp(a) screening initiative taking place?

The initiative is taking place in community health centers across the U.S., including locations in California, Texas, Virginia, New Mexico, Ohio, Connecticut, and New York.

When did the Lp(a) Community Health Centers Discovery Project start?

Ten community health centers signed onto the project in 2024, with 10 additional sites to be added in the following year.

What are the benefits of Lp(a) screening?

Lp(a) screening can help individuals understand their heart disease risk early, allowing for better management and potentially reducing the risk of ASCVD-related events like heart attacks and strokes.

How can I find out more about Lp(a) screening?

For more information, you can visit the American Heart Association’s website or contact participating community health centers directly.